By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Virttu Biologics 

PO Box 1716

  Glasgow  G51 4WF  United Kingdom
Phone: 44-0-141-445-1716 Fax: 44-0-141-445-1715



Company News
Sorrento (SRNE) Announces Closing Of Its Acquisition Of Virttu Biologics 4/28/2017 8:47:34 AM
Sorrento (SRNE)'s TNK Therapeutics Subsidiary To Acquire Virttu Biologics 11/17/2016 7:14:34 AM
Virttu Biologics To Present At Biotech Showcase 2016 In San Francisco 1/6/2016 10:02:43 AM
Data Demonstrating That SEPREHVIR (Virttu Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research. 11/9/2015 7:01:33 AM
Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer 10/19/2015 8:04:20 AM
Oncolytic Virus Specialist Virttu Biologics Confirms Treatment of First Cohort of Patients in Phase I/II SEPREHVIR® Study in Mesothelioma 8/26/2013 2:31:13 PM
As Field Hots Up, Virttu Biologics Secures U.S. Patent Allowance on Next-Generation Oncolytic Virus Candidates Engineered to Express Antisense Sequences 6/25/2013 11:06:36 AM
Virttu Biologics U.S. Phase I Pediatric Study is Extended to Include Systemic Delivery of Oncolytic Virus 5/31/2013 10:13:09 AM
New Virttu Biologics Replicate Open Innovation Forum Provides Unique R&D Network for New Oncology Combination Therapies 11/5/2012 12:10:50 PM
Oncolytic Virus Specialist Virttu Biologics Initiates Phase I/II SEPREHVIR™ Study in Mesothelioma 9/11/2012 11:31:41 AM